Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2152-2159

  Heiland, Gisela Ruiz ^a   Zwerina, Karin ^a   Baum, Wolfgang ^a   Kireva, Trayana ^a   Distler, Jörg H ^a   Grisanti, Mario ^b   Asuncion, Frank ^b   Li, Xiadong ^b   Ominsky, Michael ^b   Richards, William ^b   Schett, Georg ^a   Zwerina, Jochen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; OSTEOCALCIN; OSTEOPROTEGERIN; SCLEROSTIN; TUMOR NECROSIS FACTOR INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEDIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; GENETIC MARKERS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 78649723963     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.132852     Document Type: Article

References (32)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
3. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7. (Pubitemid 24199420)
4. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9.
5. Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck study. Arch Intern Med 2006;166:2495-501.
6. Goldring SR. Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003;73:97-100.
7. Gravallese EM, Harada Y, Wang JT, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
8. Schett G, Teitelbaum SL. Osteoclasts and Arthritis. J Bone Miner Res 2009;24:1142-6.
9. Polzer K, Joosten L, Gasser J, et al. Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 2010;69:284-90.
10. Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009;24:1572-85.
11. Zwerina J, Tuerk B, Redlich K, et al. Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2006;8:R22.
12. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
13. Vincent C, Findlay DM, Welldon KJ, et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009;24:1434-49.
14. Franck H, Ittel TH, Tasch O, et al. Osteocalcin in patients with rheumatoid arthritis. A one-year followup study. J Rheumatol 1994;21:1256-9. (Pubitemid 24234661)
15. Yudoh K, Matsuno H, Osada R, et al. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum 2000;43:2178-88.
16. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
17. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
18. Grigoriadis AE, Schellander K, Wang ZQ, et al. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 1993;122:685-701.
19. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23.
20. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19.
21. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116:1202-9.
22. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805-14.
23. Bhat BM, Allen KM, Liu W, et al. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene 2007;391:103-12.
24. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009;27:265-71.
25. Morvan F, Boulukos K, Clément-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45.
26. MacDonald BT, Joiner DM, Oyserman SM, et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007;41:331-9.
27. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94. (Pubitemid 38010074)
28. Voskaridou E, Christoulas D, Xirakia C, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009;94:725-8.
29. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
30. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64.
31. Sambrook PN, Hughes DR, Nelson AE, et al. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann Rheum Dis 2003;62:1215-7.
32. Qiu S, Rao DS, Fyhrie DP, et al. The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 2005;37:10-15.